secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEPHROS INC (NEPH)
CIK:        0001196298
Form:       8-K
Filed at:   2021-07-12T23:59:59+00:00
Accession:  0001493152-21-016611
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nephros acquires GenArraytion for $1.2M in stock; gains PCR pathogen detection tech
--------------------------------------------------------------------------------

- Purchase price of $1.2M paid via 123,981 shares of Nephros common stock.
- 50% of shares subject to forfeiture until intellectual property transition services completed.
- Nephros to pay royalties on net sales of GenArraytion products over five years.
- Registration statement covering issued shares must be filed within 60 days.
- GenArraytion CEO Dr. Schaudies partners with Nephros VP Dr. Smith on product integration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1196298/000149315221016611/0001493152-21-016611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1196298/000149315221016611/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-016611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer